Vitamin E and the NMDA receptor antagonist
memantine, have been shown to have beneficial effects in
moderately severe Alzheimer disease (AD). Now, a new large
randomized controlled trial in the January issue of JAMA shows
that for patients with mild to moderate Alzheimer disease (AD), 2000 IU
of vitamin E daily slows functional decline and reduces caregiver
burden. Neither memantine nor the combination of vitamin E and
memantine showed clinical benefit in the study, the authors report.